Dostinex Pfizer 0.5mg cabergoline tablets box

Dostinex (Cabergoline) 0.5mg by Pfizer

Dostinex 0.5 mg by Pfizer is a pharmaceutical-grade oral dopamine agonist containing cabergoline, available in tablet form. Cabergoline is a synthetic ergoline derivative that acts as a selective dopamine D2 receptor agonist, structurally designed to suppress prolactin secretion from the anterior pituitary gland, contributing to its distinct pharmacological profile in clinical research.

📦 Product Specifications

Manufacturer: Pfizer
Form: Oral 8 tablets per box
Molecule: Cabergoline (ergoline derivative)
Concentration: 0.5 mg per tablet
Dosage considerations may vary. Consulting a qualified healthcare professional is recommended.

✔ Key Research Insights

Researched for its role in selectively binding dopamine D2 receptors in the anterior pituitary, suppressing prolactin secretion
Studied for its efficacy in treating hyperprolactinemic disorders, both idiopathic and secondary to pituitary adenomas
Investigated for its extended half-life enabling twice-weekly dosing protocols with sustained prolactin normalization
Researched for its favorable tolerability profile relative to earlier ergot-derived dopamine agonists in clinical observations

⚙ How It Works

Cabergoline is an orally active dopamine D2 receptor agonist that exerts potent and prolonged inhibitory action on prolactin secretion from lactotroph cells of the anterior pituitary. In research subjects, it demonstrates high binding selectivity for the D2 receptor subtype, which is associated with significant and dose-dependent reductions in serum prolactin levels. Its extended pharmacokinetic half-life supports a twice-weekly dosing interval, distinguishing it from shorter-acting agents in the same class. Cabergoline does not interact with the aromatase enzyme and has no direct androgenic or estrogenic activity. Clinical observations note that prolactin normalization may be maintained for sustained periods, with some subjects retaining normal serum levels following discontinuation after 6 months of stable response.

⚠ Clinical Considerations

Cardiovascular evaluation is recommended prior to initiation; echocardiography should be considered to assess for valvular disease, particularly in long-term use
Dosage escalation should not occur more rapidly than every 4 weeks to allow adequate assessment of patient response at each level
Not recommended for female research subjects who are pregnant or may become pregnant without prior medical evaluation
Patients on long-term protocols should undergo periodic cardiac status assessment and echocardiographic monitoring

⭐ Product Overview

Manufactured by Pfizer, a globally recognized pharmaceutical company with established GMP standards
Consistent tablet formulation with precise cabergoline concentration and score line for accurate dose titration
Established compound with an extensive clinical and pharmacological research history in hyperprolactinemia management
High manufacturing standards and pharmaceutical-grade quality assurance

Dostinex Thailand – Pfizer Cabergoline 0.5mg

THB 1,400.00

Quantity

Dostinex is a brand-name medication manufactured by Pfizer. Its active ingredient is cabergoline, a dopamine agonist that works by reducing the release of prolactin from the pituitary gland. It is primarily prescribed to treat hyperprolactinemia - a condition where prolactin levels in the blood are abnormally high - which can cause irregular menstrual cycles, unwanted breast milk production, and fertility problems in women, as well as reduced libido and enlarged breast tissue in men. Dostinex is taken orally twice a week and is considered the first-line treatment for prolactin-related hormonal disorders due to its long half-life and favorable tolerability profile compared to older alternatives such as bromocriptine.
Cabergoline is the active pharmaceutical ingredient - the molecule that produces the therapeutic effect. Dostinex is the original brand name under which Pfizer markets cabergoline globally. Both contain exactly the same active substance at the same concentration (0.5 mg per tablet), so their clinical effectiveness and side effect profile are identical. The practical difference lies in price and availability: generic cabergoline is typically sold at a lower price point, while Dostinex (Pfizer) is the original, widely recognized reference product. When purchasing either form, you are getting the same dopamine agonist that lowers elevated prolactin levels.
The standard starting dose of Dostinex is 0.25 mg taken twice per week. Your doctor may gradually increase the dose - no faster than every four weeks - up to a maximum of 1 mg twice weekly, based on your prolactin blood test results and individual response to treatment. Dostinex 0.5 mg tablets are scored, making it easy to split them for lower starting doses. The tablets should be taken with food to reduce the risk of nausea. Always follow your physician's instructions - do not adjust the dose on your own, as prolactin levels must be monitored throughout the course of treatment.